

Procedure Not Routinely Funded
contact Bedfordshire MSK service (Circle Bedfordshire)
NHS England Evidence Based Intervention (EBI) Statement

Number	96
Subject	Management of Dupuytren's Contracture
Date of decision	September 2018
Date of refresh	December 2019: NHSE EBI¹ statement added
Date of review	September 2021

GUIDANCE

Intervention

Dupuytren's contracture is caused by fibrous bands in the palm of the hand which draw the finger(s) (and sometimes the thumb) into the palm and prevent them from straightening fully. If not treated the finger(s) may bend so far into the palm that they cannot be straightened. All treatments aim to straighten the finger(s) to restore and retain hand function for the rest of the patient's life. However none cure the condition which can recur after any intervention so that further interventions are required.

Splinting and radiotherapy have not been shown be effective treatments of established Dupuytren's contractures.

Several treatments are available: collagenase injections, needle fasciotomy, fasciectomy and dermofasciectomy. None is entirely satisfactory with some having slower recovery periods, higher complication rates or higher reoperation rates (for recurrence) than others. The need for, and choice of, intervention should be made on an individual basis and should be a shared decision between the patient and a practitioner with expertise in the various treatments of Dupuytren's contractures.

No-one knows which interventions are best for restoring and maintaining hand function throughout the rest of the patient's life, and which are the cheapest and most cost-effective in the long term. Ongoing and planned National Institute for Health Research studies aim to address these questions.

Recommendation

- Treatment is not indicated in cases where there is no contracture, and in patients with a mild (less than 20°) contractures, or one which is not progressing and does not impair function.

¹ <https://www.england.nhs.uk/evidence-based-interventions/ebi-programme-guidance/>

- An intervention (collagenase injections, needle fasciotomy, fasciectomy and dermofasciectomy) should be considered for:
 - a. finger contractures causing loss of finger extension of 30° or more at the metacarpophalangeal joint or 20° at the proximal interphalangeal joint. or
 - b. severe thumb contractures which interfere with function

NICE concluded that collagenase should only be used for:

- a. Participants in the ongoing clinical trial (HTA-15/102/04) or
- b. Adult patients with a palpable cord if:
 - i. there is evidence of moderate disease (functional problems and metacarpophalangeal joint contracture of 30° to 60° and proximal interphalangeal joint contracture of less than 30° or first web contracture) plus up to two affected joints; and
 - ii. needle fasciotomy is not considered appropriate, but limited fasciectomy is considered appropriate by the treating hand surgeon

Rationale

Contractures left untreated usually progress and often fail to straighten fully with any treatment if allowed to progress too far. Complications causing loss, rather than improvement, in hand function occur more commonly after larger interventions, but larger interventions carry a lower risk of need for further surgery.

Common complications after collagenase injection are normally transient and include skin breaks and localised pain. Tendon injury is possible but very rare. Significant complications with lasting impact after needle fasciotomy are very unusual (about 1%) and include nerve injury. Such complications after fasciectomy are more common (about 4%) and include infection, numbness and stiffness.

OPCS codes:

T52.1 Palmar fasciectomy

"X65.4

WITH

Z91.9 "Delivery of a fraction of external beam radiotherapy NEC"

WITH

Z89.4" Unspecified external beam radiotherapy Hand NEC"

ICD10 codes:

M72.0 Dupuytren's contracture

References

1. http://www.bssh.ac.uk/_userfiles/pages/files/Patients/Conditions/Elective/dupuytren's_disease_leaflet_2016.pdf

2. <https://cks.nice.org.uk/dupuytren-s-disease>

3. Crean SM, Gerber RA, Le Graverand MP, Boyd DM, Cappelleri JC. The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies. J Hand Surg Eur Vol. 2011;36(5):396-407.

4. Krefter C, Marks M, Hensler S, Herren DB, Calcagni M. Complications after treating Dupuytren's disease. A systematic literature review. *Hand surgery & rehabilitation*. 2017, 36: 322-9.
5. NICE 2004. Needle fasciotomy for Dupuytren's contracture. <https://www.nice.org.uk/guidance/ipg43>
6. NICE, 2017. Collagenase clostridium histolyticum for treating Dupuytren's contracture. : <https://www.nice.org.uk/guidance/ta459>
7. Rodrigues JN, Becker GW, Ball C, Zhang W, Giele H, Hobby J, et al. Surgery for Dupuytren's contracture of the fingers. *Cochrane Database Syst Rev*. 2015(12):CD010143.
8. Scherman P, Jenmalm P, Dahlin LB. Three-year recurrence of Dupuytren's contracture after needle fasciotomy and collagenase injection: a two-centre randomized controlled trial. *J Hand Surg Eur Vol*. 2018;43(8):836-40.
9. Skov ST, Bisgaard T, Sondergaard P, Lange J. Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial. *J Hand Surg Am*. 2017;42(5):321-8 e3.
10. Stromberg J, Ibsen Sorensen A, Friden J. Percutaneous Needle Fasciotomy Versus Collagenase Treatment for Dupuytren Contracture: A Randomized Controlled Trial with a Two-Year Follow-up. *J Bone Joint Surg Am*. 2018;100(13):1079-86.
11. van Rijssen AL, Gerbrandy FS, Ter Linden H, Klip H, Werker PM. A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: A 6-week follow-up study. *J Hand Surg Am*. 2006, 31: 717-25.
12. van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: Percutaneous needle fasciotomy versus limited fasciectomy. *Plast Reconstr Surg*. 2012, 129: 469-77.

Equalities and Human Rights Legislation has been considered in the development of this guidance